Basic information of MDAI:

(1)CAS No.: ;
(2)Other Names: MDAI;
(3)MF: C₁₂H₁₅NO₃.ClH;
(4))Color:brown.

e (MDAI) is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non-neurotoxic and highly selective serotonin releasing agent in vitro and produces entactogen effects in humans. MDAI has been shown to inhibit the reuptake of serotonin, dopamine, and norepinephrine with IC50 values of 512nM, 5,920nM, and 1,426nM, respectively. This demonstrates that MDAI has selective affinity for the serotonin transporter. In animals treated with reserpine and MDAI, greater extracellular concentrations of monoamine neural transmitters resulted, most significantly serotonin. This result indicates that MDAI is a potent releaser of serotonin, while effectively inhibiting the reuptake of serotonin. For comparison, MDAI is similar in potency with releasing serotonin to MDA but significantly less potent than M.

MDAI and other similar drugs have been widely used in scientific research, as they are able to replicate many of the effects of MDMA, but without causing the neurotoxicity which may be associated with MDMA and some related drugs. MDAI has been advertised as a designer drug. An analysis of two products on sale on the internet in June 2010 found that one contained mephedrone and that the other had an inorganic composition. Neither contained MDAI.